DIM 6 J Stay Stay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

) Art Unit: 1654 Application of : Chen, S. et al. WARD, Edward C. U.S. Appln. No. : 10/620,408) Examiner: Confirmation No.: 1543 U.S. Filing Date : 07/16/2003 Title of Invention: Pharmaceutical Compositions for Hepatitis C Viral Protease Inhibitors Attny. Docket No.: 9/248 Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 June 4, 2004 TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT Sir: Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow. Also enclosed is the International Search Report (ISR) issued in the corresponding international application, and citing (PCT/US 03/22434) the U.S. and International patents that are cited herein. This Statement is being filed: i) within three (3) months of the filing 1.97(b). date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. \bowtie This Statement is being filed after the time period specified in 37 1.97(c). C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by: A statement as specified in 37 C.F.R. §1.97(e) [see below]; or \boxtimes The fee set forth in 37 C.F.R. §1.17(p).

06/09/2004 RMEBRAHT 00000130 022955 10620408

01 FC:1806

180.00 DA

		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e).
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a expart foreign application not more than three (3) months prior to the filing of stant information disclosure statement; or
	foreign makin inform §1.56(No item of information contained in the instant information disclosure tent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after ig reasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37 C.F.R (c) more than three (3) months prior to the filing of the instant information sure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap	(d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a opplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying isclosure statement

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4542 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on June 4, 2004

Platip I. Datlow, Reg. No. 41,482

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/620,408 Filing Date 07/16/2003 First Named Inventor Chen, S., et al. Art Unit 16**5**4 **Examiner Name** WARD, EDWARD C.

(Use as many sheets as necessary) Attorney Docket Number 9/248 1


			U. S. PATENT DOCUMENTS		
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 2003 0195228 A1	10-16-2003	Shirlynn Chen, et al.	
		US-			
		US-			
***************************************		US-			
		US-			
		US-	······································		
		US-			
		US-			
	ļ	US-			
		US-			
		US-			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		US-			
····		US-			
		US-			
and the second s		US-			
		US-			
		US-	····		
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
		WO 99/06044	02-11-1999	PHARMACIA & UPJOHN COMPANY		

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





1

APPLICANT(S):

Chen, S. et al

SERIAL NO.:

10/620,408

CONFIRMATION NO.: 1543 FILING DATE: 07/16

07/16/2003

DOCKET NO.:

9/248

TITLE:

7/240

IIILE:

Pharmaceutical Compositions

for Hepatitis C Viral Protease Inhibitors

IN CONNECTION WITH THE ABOVE CASE, PLEASE DATE STAMP TO ACKNOWLEDGE RECEIPT OF THE DOCUMENTS LISTED BELOW, AND RETURN TO ADDRESSEE.

- 1. Transmittal Letter for Information Disclosure Statement (In Triplicate);
- 2. Information Disclosure Statement By Applicant;
- 3. Copies of all references;
- 4. International Search Report

Mailed: February 23, 2004







APPLICANT(S):

Chen, S. et al

SERIAL NO.:

10/620,408

CONFIRMATION NO.: 1543

1543

FILING DATE:

07/16/2003

DOCKET NO.:

9/248

TITLE:

Pharmaceutical Compositions

for Hepatitis C Viral Protease Inhibitors

IN CONNECTION WITH THE ABOVE CASE, PLEASE DATE STAMP TO ACKNOWLEDGE RECEIPT OF THE DOCUMENTS LISTED BELOW, AND RETURN TO ADDRESSEE.

- 1. Transmittal Letter for Information Disclosure Statement (In Triplicate);
- 2. Information Disclosure Statement By Applicant;
- 3. Copies of all references;
- 4. International Search Report

Mailed: February 23, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Chen, S. et al. U.S. Appln. No. : 10/620,408) Art Unit:) Examiner:	1614 Not known
Confirmation No.: 1543 U.S. Filing Date: 07/16/2003 Title of Invention: Pharmaceutical Compattny. Docket No.: 9/248	positions for Hepatitis (C Viral Protease Inhibitors
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
February 23, 2004		
TRANSMITTAL LETTER FOR IN	FORMATION DISCI	OSURE STATEMENT
Sir:		
Transmitted herewith concerning the subj Statement (Form 1449A/B) under 37 C.F. hereinbelow.	ect application is an Info.R. §§1.56 and 1.97, as a	ormation Disclosure more specifically described
Also enclosed is the International Search international application, and citing (PCT) that are cited herein.	Report (ISR) issued in t /US 03/22434) the U.S.	he corresponding and International patents
1.97(b). This Statement is be date of a national application other than a §1.53 (d); ii) within three (3) months of the 37 C.F.R. §1.491 in an international application on the merits; or iv) before the mailing of continued examination under 37 C.F.R. §	continued prosecution and date of entry of the nation; iii) before the marks a first Office action after	ational stage as set forth in ailing of a first Office action
1.97(c). This Statement is be C.F.R. §1.97(b), but before the mailing da notice of allowance under 37 C.F.R. §1.3 in the application. This Statement is bein	11, or iii) an action that	nder 37 C.F.R. §1.113, ii) a
A statement as specified in	n 37 C.F.R. §1.97(e) [se	ee below]; or
The fee set forth in 37 C.F	.R. §1.17(p).	

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
§1.97(c)	97(d). This Statement is being filed after the period specified in 37 C.F.R. but on or before payment of the issue fee. This Statement is accompanied by a not as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. b.
<u> </u>	.97(e).
C	Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
f r i §	No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
[The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosu counterr in section	1.704(d). Each item of information contained in the accompanying information are statement was cited in a communication from a foreign patent office in a part application, which communication was not received by any individual designated on 1.56(c) more than thirty (30) days prior to the filing of the accompanying tion disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

hilip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4542 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on February 23, 2004

Philip I. Datlow, Reg. No. 41,482

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ubstitute for form 1449A/PTO			Co	mplete if Known
Ū				Application Number	10/620,408
ı	NFORMATION D	ISCLO	SURE	Filing Date	07/16/2003
	STATEMENT BY			First Named Inventor	Chen, S., et al.
•	JIAILMENT DI			Art Unit	1614
	(Use as many sheets	as necessarv)		Examiner Name	Not Known
Sheet	T 4	of	2	Attorney Docket Number	9/248

Examiner	Cito	Dogument Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages Columns Lines Where
Examiner Initials*	Cite No.1	Document Number	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
	140.	Number-Kind Code ^{2 (# known)}	WIW-DD-1111	Applicant of Orea Document	Figures Appear
		US-		1	
		US-			
		US-		·	
		US-			
		US-			
		US-			
water housewarder tres		US-			
		US-			
	*************	US-			
		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			<u> </u>
	·····	US-			
		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
	······································	US-			·
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T [®]
	,	Country Code ³ Number ⁴ Kind Code ⁵ (# known) WO 99/07733	02/18/1999	Boehringer Ingelheim (Canada) LTD.	or Relevant Figures Appear	╁
		WO 00/09543	02/24/2000	Boehringer Ingelheim (Canada) LTD.	••••••••••••••••••••••••••••••••••••••	-
		WO 03/066103	08/14/2003	Boehringer Ingelheim Pharmaceuticals, Inc.		十
		***************************************				Г
			***************************************		**************************************	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	form 1449B/PTO				Complete if Known	
				Application Number	10/620,408	
INFO	RMATION D	ISCLOS	SURE	Filing Date	07/16/2003	
STAT	EMENT BY	APPLIC	CANT	First Named Inventor	Chen, S., et al.	
				Art Unit	1614	
	(Use as many sheets a	s necessary)		Examiner Name	Not Known	
Sheet	2	of	2	Attorney Docket Number	9/248	

Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. "Remington's Pharmaceutical Sciences" 1975, Mack Publishing Company, Easton, PA, USA, XP002262427 "Tromethamine" pg 773	MENTS	
"Remington's Pharmaceutical Sciences" 1975, Mack Publishing Company, Easton, PA, USA, XP002262427 "Tromethamine" pg 773	page(s), volume-issue number(s), publisher, city	
	ublishing Company, Easton, PA, USA,	

			1	1
			_	i
Examiner	,		Date	
Signature		•	I Considered	i .
Colginatore			Considered	L

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.